Clinical Trial Update: Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

A Phase II trial comparing Salmeterol inhalation powder delivered by HandiHaler 2 versus Serevent Diskus in COPD, evaluating efficacy, pharmacokinetics, and saf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Salmeterol inhalation powder (HandiHaler 2) (salmeterol)
• Salmeterol inhalation powder (Serevent Diskus) (salmeterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED